MicroRNA ‐1307‐3p contributes to breast cancer progression through PRM2
Thoracic Cancer · 2024-11 · 15 (32) · 2298-2308
DOI: 10.1111/1759-7714.15460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 09.10.2024. Verfasst von José Roberto Estupiñan-Jiménez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Departmento de Biología Celular y Genética, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico. Hauptthemen laut MEDLINE: MicroRNAs, Breast Neoplasms, Cell Proliferation, Cell Movement. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of General Medical Sciences-Research Training Initiative for Student Enhancement (NIGMS-RISE) Program, National Institute of General Medical Sciences (NIGMS) Support for Research Excellence (SuRE) Program (R16) grant, Programa Presupuestario F003, CB2017-2018, CONAHCYT.
Abstract (Originalsprache)
Background
Despite advances in screening and therapy, breast cancer (BC) remains the predominant cancer in women globally. Dysregulation of microRNAs (miRNAs) is pivotal in carcinogenesis across various cancers, including BC. Evidence indicates that miR‐1307‐3p is upregulated in BC tumors, yet its target genes are not fully elucidated. This study aimed to explore how miR‐1307‐3p regulates BC proliferation, migration, invasion, and angiogenesis and to identify potential target genes.
Methods
Basal miR‐1307‐3p levels were quantified in BC cell lines MDA‐MB‐231 and MCF‐7, as well as MCF‐10A using quantitative real‐time reverse transcription‐PCR (RT‐qPCR). The impact of miR‐1307‐3p inhibition on BC cell proliferation, migration, invasion, and angiogenesis was assessed. Nine miRNA‐target prediction databases identified potential miR‐1307‐3p targets. Target expression was validated using RT‐qPCR, Western blot, and dual‐luciferase reporter assays. MiR‐1307‐3p was overexpressed in MDA‐MB‐231 and MCF‐7 compared to MCF‐10A.
Results
Inhibiting miR‐1307‐3p significantly reduced BC cell proliferation, migration, invasion, and angiogenesis. Bioinformatics analysis identified 17 potential miR‐1307‐3p targets, with protamine 2 (PRM2) overexpression confirmed via Western blot and dual‐luciferase assays.
Conclusion
MiR‐1307‐3p overexpression in BC promotes proliferation, migration, invasion, and angiogenesis. PRM2 emerges as a novel miR‐1307‐3p target in BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departmento de Biología Celular y Genética, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.
- Department of Biochemistry, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.
- Comprehensive Cancer Center, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.
- Laboratorio de Inmunología y Virología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.
- Laboratorio de Micología y Fitopatología, Unidad de Manipulación Genética, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.
- Departamento de Química, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.
ORCID-Profile: José Roberto Estupiñan-Jiménez, Jose Manuel Vazquez-Guillen
Förderung
- National Institute of General Medical Sciences-Research Training Initiative for Student Enhancement (NIGMS-RISE) Program
- National Institute of General Medical Sciences (NIGMS) Support for Research Excellence (SuRE) Program (R16) grant
- Programa Presupuestario F003, CB2017-2018, CONAHCYT
- NIGMS NIH HHS
- Institutional seed funds from the University of Puerto Rico Comprehensive Cancer Center
- National Institute of General Medical Sciences
Zitieren
APA
Estupiñan-Jiménez, J. R., Villarreal-García, V., Gonzalez-Villasana, V., Vivas-Mejia, P. E., Vazquez-Guillen, J. M., Zapata-Morin, P. A., Flores-Colón, M., Altamirano-Torres, C., Viveros-Valdez, E., Ivan, C., Rashed, M. H., Bayraktar, R., Rodríguez-Padilla, C., Lopez-Berestein, G., & Resendez-Perez, D. (2024). MicroRNA ‐1307‐3p contributes to breast cancer progression through PRM2. Thoracic Cancer, 15(32), 2298-2308. https://doi.org/10.1111/1759-7714.15460
Vancouver
Estupiñan-Jiménez JR, Villarreal-García V, Gonzalez-Villasana V, Vivas-Mejia PE, Vazquez-Guillen JM, Zapata-Morin PA, et al. MicroRNA ‐1307‐3p contributes to breast cancer progression through PRM2. Thoracic Cancer. 2024;15(32):2298-2308. doi:10.1111/1759-7714.15460
BibTeX
@article{EstupianJimnez2024,
author = {Estupiñan-Jiménez, José Roberto and Villarreal-García, Valeria and Gonzalez-Villasana, Vianey and Vivas-Mejia, Pablo E and Vazquez-Guillen, Jose Manuel and Zapata-Morin, Patricio Adrián and Flores-Colón, Marienid and Altamirano-Torres, Claudia and Viveros-Valdez, Ezequiel and Ivan, Cristina and Rashed, Mohammed H and Bayraktar, Recep and Rodríguez-Padilla, Cristina and Lopez-Berestein, Gabriel and Resendez-Perez, Diana},
title = {MicroRNA ‐1307‐3p contributes to breast cancer progression through PRM2},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {32},
pages = {2298--2308},
doi = {10.1111/1759-7714.15460}
}
EUVIMED